Frovatriptan (succinate hydrate)

Frovatriptan succinate hydrate ((R) -Frovatriptan succinate hydrate) is a potent, high affinity, selective and orally active 5-HT1B (pK50 of 8.2) and 5-HT1D receptor agonist. Frovatriptan succinate hydrate exhibits >10-fold selectivity for 5-HT1B and 5-HT1D over 5-HT1A, 5-HT1F, and 5-HT7 and >1000-fold selectivity over other 5-HT, dopamine, histamine H1, and α1-adrenoceptor. Frovatriptan succinate hydrate has the potential for migraine research[1][2].

Product Specifications

CAS Number

[158930-17-7]

Product Name Alternative

(R) -Frovatriptan (succinate hydrate) ; SB 209509 (succinate hydrate) ; VML 251 (succinate hydrate)

UNSPSC

12352005

Hazard Statement

H302, H319, H332, H361

Target

5-HT Receptor

Type

Reference compound

Related Pathways

GPCR/G Protein; Neuronal Signaling

Applications

Neuroscience-Neuromodulation

Field of Research

Neurological Disease

Assay Protocol

https://www.medchemexpress.com/frovatriptan-succinate-hydrate.html

Concentration

10mM

Purity

99.91

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

O=C(O)CCC(O)=O.O=C(C1=CC2=C(NC3=C2C[C@H](NC)CC3)C=C1)N.O

Molecular Formula

C18H25N3O6

Molecular Weight

379.41

Precautions

H302, H319, H332, H361

References & Citations

[1]Kelman L. Review of frovatriptan in the treatment of migraine. Neuropsychiatr Dis Treat. 2008 Feb;4 (1) :49-54.|[2]Comer MB. Et al. Pharmacology of the selective 5-HT (1B/1D) agonist frovatriptan. Headache. 2002 Apr;42 Suppl 2:S47-53.